CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
30 active trials across 10 therapeutic areas
30
Active Trials
10
Phase 1
15
Phase 2
13
Phase 3
10
Therapeutic Areas
Portfolio Concentration: 70% of active trials in Oncology
Oncology
21 active / 34 total
Breast Cancer
5 active
2 Ph3
6 total since 2015
Non-Hodgkin Lymphoma
2 active
1 Ph3
6 total since 2015
AML
2 active
3 total since 2015
Gastric Cancer
2 active
1 Ph3
2 total since 2015
HER2+ Breast Cancer
2 active
1 Ph3
2 total since 2015
Solid Tumor (Advanced)
1 active
2 total since 2015
Hepatocellular Carcinoma
1 active
1 total since 2015
Neuroendocrine Tumors
1 active
1 Ph3
1 total since 2015
NSCLC
1 active
1 total since 2015
Pancreatic Cancer
1 active
1 Ph3
1 total since 2015
ALL
1 active
1 total since 2015
Cervical Cancer
1 active
1 Ph3
1 total since 2015
Multiple Myeloma
1 active
1 total since 2015
Sarcoma
0 active
1 total since 2015
Ovarian Cancer
0 active
1 total since 2015
Head and Neck Cancer
0 active
1 total since 2015
SCLC
0 active
1 total since 2015
Cholangiocarcinoma
0 active
1 total since 2015
Triple Negative Breast Cancer
0 active
1 total since 2015
Immunology
4 active / 6 total
Respiratory
3 active / 4 total
Cardiovascular
2 active / 2 total
CNS
1 active / 3 total
Metabolic
0 active / 8 total
Urology
0 active / 2 total
Renal
0 active / 1 total
Pain
0 active / 1 total
Endocrine
0 active / 1 total
Click an indication to see competitive landscape (all sponsors in that indication).
Data: ClinicalTrials.gov (2015+)